pharmaceuticals

March 26, 2021, 9:05 am

The decision of the Controller of Patent to revoke Novartis’ patent on the anti-cancer drug Ceritinib, was quashed by the Intellectual Property Appellate Board (IPAB). This decision examines several issues concerning the novelty and obviousness, the extent of coverage and disclosure, and timelines for filing the evidence. The IPAB while quashing the decision held that... Read More

Categories: